Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it convened a Scientific Advisory Board (SAB) focusing the discussions on NT219’s indication in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
- “Their recognition of the critical unmet need in recurrent and metastatic head and neck cancer provides further support and momentum to our development program.
- Now that we have determined the recommended Phase 2 dose, we are prepared to move to our next phase of development.
- We look forward to the head and neck cancer SAB’s continued guidance and support.”
Head & Neck Cancer SAB Members Include:
Douglas Adkins, MD – Dr. Adkins is a Professor of Medicine and Director, Head and Neck and Thyroid Medical Oncology, at the Siteman Cancer Center, Washington University School of Medicine. - He is a nationally recognized expert in head and neck cancer known for his commitment to advancing patient care through clinical research.